[go: up one dir, main page]

PE20181805A1 - Composiciones y anticuerpos anti-tim-3 - Google Patents

Composiciones y anticuerpos anti-tim-3

Info

Publication number
PE20181805A1
PE20181805A1 PE2018001979A PE2018001979A PE20181805A1 PE 20181805 A1 PE20181805 A1 PE 20181805A1 PE 2018001979 A PE2018001979 A PE 2018001979A PE 2018001979 A PE2018001979 A PE 2018001979A PE 20181805 A1 PE20181805 A1 PE 20181805A1
Authority
PE
Peru
Prior art keywords
seq
tim
cdr
complementarity
refers
Prior art date
Application number
PE2018001979A
Other languages
English (en)
Inventor
Trine Lindsted
Torben Gjetting
Gunther Roland Galler
Monika Gad
Michael Monrad Grandal
Klaus Koefoed
Michael Kragh
Ivan David Horak
Thomas Bouquin
Mikkel Wandahl Pedersen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of PE20181805A1 publication Critical patent/PE20181805A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN ANTICUERPO ANTI-TIM-3 CUYAS REGIONES DETERMINANTES DE LA COMPLEMENTARIEDAD DE CADENA PESADA (H-CDR) 1-3 Y REGIONES DETERMINANTES DE LA COMPLEMENTARIEDAD DE CADENA LIGERA (L-CDR) 1-3 COMPRENDEN LAS SECUENCIAS DE AMINOACIDOS DE LAS SEQ ID NO: 7-12, RESPECTIVAMENTE, Y QUE ADEMAS SU DOMINIO VARIABLE DE CADENA PESADA (VH) COMPRENDE LAS SECUENCIAS DE AMINOACIDOS DE SEQ ID NO: 15 O 3, Y SU DOMINIO VARIABLE DE CADENA LIGERA (VL) COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 4. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE, SIENDO UTIL EN EL TRATAMIENTO DE CANCER
PE2018001979A 2016-04-12 2017-04-11 Composiciones y anticuerpos anti-tim-3 PE20181805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662321476P 2016-04-12 2016-04-12

Publications (1)

Publication Number Publication Date
PE20181805A1 true PE20181805A1 (es) 2018-11-19

Family

ID=58547516

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001979A PE20181805A1 (es) 2016-04-12 2017-04-11 Composiciones y anticuerpos anti-tim-3

Country Status (35)

Country Link
US (2) US11390674B2 (es)
EP (2) EP3978531A1 (es)
JP (2) JP7123804B2 (es)
KR (1) KR102473028B1 (es)
CN (2) CN116693685A (es)
AU (1) AU2017251250B2 (es)
BR (1) BR112018070919A2 (es)
CA (1) CA3020647A1 (es)
CL (1) CL2018002878A1 (es)
CO (1) CO2018010458A2 (es)
CY (1) CY1125440T1 (es)
DK (1) DK3443009T3 (es)
EA (1) EA039020B1 (es)
ES (1) ES2900381T3 (es)
HR (1) HRP20211820T1 (es)
HU (1) HUE056677T2 (es)
IL (1) IL262176B2 (es)
LT (1) LT3443009T (es)
MA (1) MA44659B1 (es)
MD (1) MD3443009T2 (es)
MX (1) MX2018012076A (es)
MY (1) MY199098A (es)
PE (1) PE20181805A1 (es)
PH (1) PH12018502112B1 (es)
PL (1) PL3443009T3 (es)
PT (1) PT3443009T (es)
RS (1) RS62736B1 (es)
SA (1) SA518400222B1 (es)
SG (2) SG10201912937SA (es)
SI (1) SI3443009T1 (es)
TN (1) TN2018000333A1 (es)
TW (1) TWI752950B (es)
UA (1) UA126854C2 (es)
WO (1) WO2017178493A1 (es)
ZA (1) ZA201806429B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3274370T (pt) 2015-03-23 2020-01-30 Bayer Pharma AG Anticorpos anti-ceacam6 e utilizações dos mesmos
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
JP2020513009A (ja) 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
US11787859B2 (en) 2017-08-28 2023-10-17 Bristol-Myers Squibb Company TIM-3 antagonists for the treatment and diagnosis of cancers
WO2019140229A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2019179420A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
CN111886256B (zh) 2018-03-23 2025-01-10 百时美施贵宝公司 抗mica和/或micb抗体及其用途
WO2019196911A1 (en) * 2018-04-12 2019-10-17 Nanjing Leads Biolabs Co., Ltd. Antibody binding tim-3 and use thereor
EP3785732A4 (en) * 2018-04-24 2022-02-23 Ampsource Biopharma Shanghai Inc. ANTIBODIES AGAINST TIM-3 AND USE THEREOF
KR20210045999A (ko) * 2018-08-21 2021-04-27 앨버트 아인슈타인 컬리지 오브 메디신 인간 Tim-3에 대한 모노클로날 항체
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
CA3123735A1 (en) 2018-12-19 2020-06-25 Bayer Aktiengesellschaft Pharmaceutical combination of anti ceacam6 and tim3 antibodies
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
US20220306737A1 (en) * 2019-09-16 2022-09-29 Novartis Ag Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
KR102536302B1 (ko) * 2020-02-25 2023-05-26 국립암센터 Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
WO2021171257A1 (en) * 2020-02-28 2021-09-02 Symphogen A/S Anti-axl antibodies and compositions
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
DK4267105T3 (da) 2020-12-28 2025-05-19 Bristol Myers Squibb Co Antistofsammensætninger og fremgangsmåder til anvendelse deraf
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4326773A1 (en) 2021-04-23 2024-02-28 Suzhou Neologics Bioscience Co., Ltd. Tim-3-targetting antibodies and uses thereof
US12012450B2 (en) 2021-06-01 2024-06-18 Les Laboratoires Servier Anti-NKG2A antibodies and compositions
WO2023031366A1 (en) 2021-09-02 2023-03-09 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
CA3230723A1 (en) 2021-09-03 2023-03-09 Oncoone Research & Development Gmbh Improved fc silenced anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity
EP4493575A1 (en) 2022-03-18 2025-01-22 Bristol-Myers Squibb Company Methods of isolating polypeptides
IL317319A (en) 2022-06-02 2025-01-01 Bristol Myers Squibb Co Antibody compounds and methods of using them
WO2024224323A1 (en) 2023-04-24 2024-10-31 King Abdullah University Of Science Of Technology Compositions, systems and methods for multiplex detection of target biomarkers in a sample
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
CN118373913B (zh) * 2024-05-08 2024-11-01 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118165111B (zh) * 2024-05-15 2024-08-13 中国人民解放军军事科学院军事医学研究院 针对Tim-3的抗体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
EP2252319A2 (en) 2008-01-29 2010-11-24 The Brigham and Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
JP5569946B2 (ja) 2009-01-26 2014-08-13 国立大学法人 岡山大学 免疫抑制剤および自己免疫疾患の予防および治療剤
EP2417984B1 (en) * 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
HUE040213T2 (hu) * 2010-06-11 2019-02-28 Kyowa Hakko Kirin Co Ltd Anti-TIM antitest
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
CN103936853B (zh) 2014-01-26 2016-08-17 中国人民解放军军事医学科学院基础医学研究所 一种检测tim-3试剂盒及其使用方法
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015136541A2 (en) 2014-03-12 2015-09-17 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
JP2017515841A (ja) 2014-05-13 2017-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AR103867A1 (es) 2015-03-06 2017-06-07 Sorrento Therapeutics Inc Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US11014983B2 (en) 2015-08-20 2021-05-25 Sutro Biopharma, Inc. Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
PT3356411T (pt) 2015-10-02 2021-08-30 Hoffmann La Roche Anticorpos biespecíficos específicos para pd1 e tim3
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
JP2020513009A (ja) 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

Also Published As

Publication number Publication date
CN109451741B (zh) 2023-07-28
EA201892294A1 (ru) 2019-04-30
MY199098A (en) 2023-10-12
SA518400222B1 (ar) 2022-03-14
US20190276531A1 (en) 2019-09-12
IL262176B2 (en) 2023-03-01
KR102473028B1 (ko) 2022-11-30
TN2018000333A1 (en) 2020-01-16
CL2018002878A1 (es) 2019-04-26
SG10201912937SA (en) 2020-02-27
TW201736397A (zh) 2017-10-16
BR112018070919A2 (pt) 2019-01-29
CN116693685A (zh) 2023-09-05
PH12018502112A1 (en) 2019-09-23
PL3443009T3 (pl) 2022-01-31
US11390674B2 (en) 2022-07-19
PH12018502112B1 (en) 2024-03-27
JP2019519199A (ja) 2019-07-11
CN109451741A (zh) 2019-03-08
PT3443009T (pt) 2021-12-10
SI3443009T1 (sl) 2022-04-29
CO2018010458A2 (es) 2018-10-10
AU2017251250A1 (en) 2018-10-18
EP3978531A1 (en) 2022-04-06
IL262176A (en) 2018-11-29
HRP20211820T1 (hr) 2022-03-04
JP2022172142A (ja) 2022-11-15
MA44659B1 (fr) 2021-12-31
SG11201808724SA (en) 2018-11-29
CY1125440T1 (el) 2023-03-24
IL262176B (en) 2022-11-01
WO2017178493A1 (en) 2017-10-19
ZA201806429B (en) 2023-02-22
HUE056677T2 (hu) 2022-02-28
KR20180133482A (ko) 2018-12-14
LT3443009T (lt) 2021-12-27
RS62736B1 (sr) 2022-01-31
ES2900381T3 (es) 2022-03-16
AU2017251250B2 (en) 2024-03-21
CA3020647A1 (en) 2017-10-19
UA126854C2 (uk) 2023-02-15
EP3443009B1 (en) 2021-09-08
EP3443009A1 (en) 2019-02-20
JP7123804B2 (ja) 2022-08-23
EA039020B1 (ru) 2021-11-23
MD3443009T2 (ro) 2022-02-28
DK3443009T3 (da) 2021-12-13
MA44659A (fr) 2021-04-14
MX2018012076A (es) 2019-02-20
TWI752950B (zh) 2022-01-21
US20230105714A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20161390A1 (es) Anticuerpos multiespecificos
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
BR112019011988A2 (pt) anticorpo anti-cd73 humana
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
PE20190737A1 (es) Anticuerpos anti-cd27
PE20211291A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR096687A1 (es) Anticuerpos anti-fcrh5
CL2015001895A1 (es) Anticuerpos que se unen al tl1a y sus usos
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20141151A1 (es) Proteinas de union al antigeno cd27l
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201600277A1 (ru) Высокоаффиные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh